Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06846710 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
A Phase 1 study of Psoriasis, sponsored by Jiangsu Hansoh Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
- 9
- Study locations
NCT06846710: Recruiting Phase 1 study of Psoriasis, sponsored by Jiangsu Hansoh Pharmaceutical Co..
NCT06846710 is a Phase 1 study of Psoriasis that is actively recruiting participants, run by Jiangsu Hansoh Pharmaceutical Co.. The registered enrollment target is 132 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (73% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06846710, a Phase 1 study of Psoriasis, is actively recruiting participants, sponsored by Jiangsu Hansoh Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
- 9
- Study locations
Study Summary
The study will be conducted in 2 parts (SAD for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 after a single oral dose in healthy participants. Part 2 is a multi-center, randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability, immunogenicity, PK, and PD of HS-20118 after multiple oral doses in patients with moderate to severe plaque psoriasis .
Primary Outcome
adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation
Conditions Studied
Interventions
- DRUG HS-20118
- OTHER HS-20118 placebo
Study Locations (9)
Florida
- Clinitiative - Floridian Clinical Research, LLC - Miami Lakes
- NuLine Clinical Trial Center (Network) - Pompano Beach
California
- Kinetic Clinical Research - Anaheim
Auckland
- Pacific Clinical Research Network (PCRN), Auckland - Takapuna
Christchurch
- Pacific Clinical Research Network (PCRN), Christchurch - Christchurch
Dunedin
- Momentum Clinical Research, Dunedin - Dunedin
Pukekohe
- Momentum Clinical Research, Pukekohe - Pukekohe
Upper Hutt
- Pacific Clinical Research Network (PCRN), Wellington - Upper Hutt
Wellington Region
- Momentum Clinical Research, Wellington - Mount Cook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2025-05-02 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 1 |
What NCT06846710 shows while recruiting
NCT06846710 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which HS-20118 is the first listed.
NCT06846710 lists 9 locations in 8 states (Florida, California, Auckland).
Frequently Asked Questions
What is clinical trial NCT06846710 about?
NCT06846710 is a clinical study titled "Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118". The study will be conducted in 2 parts (SAD for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 after a single oral dose in healthy participants. Part 2 is a multi-...
What is the current status of trial NCT06846710?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2025-05-02. Estimated completion is 2027-02-28.
What conditions does trial NCT06846710 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT06846710?
The interventions under investigation include: HS-20118 (DRUG), HS-20118 placebo (OTHER).
Who is sponsoring clinical trial NCT06846710?
This trial is sponsored by Jiangsu Hansoh Pharmaceutical Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06846710 being conducted?
This trial has 9 study locations across California, Florida, Auckland, Christchurch, Dunedin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06846710's enrollment target sits among peer trials
132 50th of 125 higher than 75 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
-
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI